Compositions and methods for treatment of thyroid eye disease
AssigneeViridian Therapeutics, Inc.
InventorsVahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
Life of this patent
Estimating the term…
Abstract
Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS), by inhibiting the activity of IGF-1R with such antibodies and compositions.
Claims23
A method of treating thyroid eye disease (TED) in a human subject having TED and in need thereof, the method comprising administering an anti-IGF-1R antibody to the human subject,
- wherein the anti-IGF-1R antibody comprises a light chain comprising a LCDR1 having an amino acid sequence of SEQ ID NO:
- 53, a LCDR2 having an amino acid sequence of SEQ ID NO:
- 54, and a LCDR3 having an amino acid sequence of SEQ ID NO:
- 55, and a heavy chain comprising a HCDR1 having an amino acid sequence of SEQ ID NO:
- 56, a HCDR2 having an amino acid sequence of SEQ ID NO:
- 57, and a HCDR3 having an amino acid sequence of SEQ ID NO:
- 58.
Dependencies are inferred from the claim text.